Researchers compared rates of gout medication initiation among patients with gout and type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists.
In a landmark study published in the journal Nature, researchers have achieved the unthinkable: a potential cure for this rare but deadly skin disease. The breakthrough came from an international team ...